MV Platform for Rare Disease

About STRM.BIO

STRM.BIO is a private, preclinical-stage biotech founded in 2020, headquartered in Cambridge, Massachusetts, with a focus on RNA and gene therapy. The company's core technology is its megakaryocyte-derived vesicle (MV) platform, designed for precise, efficient, and repeatable in vivo delivery of genetic cargo to the bone marrow. Led by an experienced team with deep industry backgrounds, STRM.BIO aims to build a diversified pipeline from a common platform foundation, targeting significant unmet needs in rare diseases and immuno-oncology. The company is currently pre-revenue and in the platform validation and early pipeline development phase.

Therapeutic Areas

Other Fanconi anemia Drugs